ArticleTranslational lung cancer research2021

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?-a trial-level meta-analysis in PD-L1 selected subgroups.

Francesco Passiglia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.